Clinical Trial Search

Primary: Change From Baseline in Average Daily Opioid Dose in Morphine Milligram Equivalents (MME) at Month 12 — -11.6; -6.0 Morphine Milligram Equivalents (MME) — p=0.31

Primary: Number of Participants With a Composite Safety Endpoint Adverse Event (AE) — 2; 6; 16; 5 Participants

Primary: ROC AUCs (MCI/AD vs Cognitively Unimpaired (CU)) for Medial Temporal Lobe (MTL) UCB-J Distribution Volume Ratio (DVR) and Hippocampal Volume — 0.79; 0.81 probability…

Primary: Number of Participants With Adverse Events (AEs) — 3; 3; 15; 1 participants

Primary: Postoperative Opioid Use — 25; 20 MMEs

Primary: Least Squares Mean (Standard Error) [LS-mean (SE)] Change From Baseline in WOMAC Pain Subscale Score at Week 12 — -2.959; -2.847 score on a scale

Primary: Number of Participants With Hemostasis of Active Bleeding — 239 Participants

Primary: Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at…

Primary: Change in Clozapine Prescriptions Using Medicaid Claims Data — 9.4; 10.8; 11.8; 9.5 Mean percent of Clozapine prescriptions

Primary: A1c </= 6.5% and no Severe Hypoglycemia — 0.667 Proportion of participants

Primary: Change in Global Cognition Assessed by RBANS — 434.66; 435.36; 438.46; 436 Score on a Scale — p=0.9644

Primary: Maximum Average Pressure at Baseline With Pressure Alternating Shoes, Right Foot (Before Any Cells Were Offloaded) — 118.5; 113.7; 96.6; 54.9 kPa

Primary: ADHD-RS Change From Baseline to Endpoint — 11.85; 10.92 units on a scale — p=.779

Primary: Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug — 2; 1; 3; 3 Participants

Primary: Number of Subjects With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies/ml — 19 Participants